Brita Schulze
MediGene
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brita Schulze.
International Journal of Cancer | 2003
Senat Krasnici; Alexander Werner; Martin E. Eichhorn; Marcus Schmitt-Sody; S. Pahernik; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Kurt Naujoks; Marc Dellian
Recently, cationic liposomes have been shown to preferentially target the angiogenic endothelium of tumors. It was the aim of our study to investigate the influence of liposomal surface charge on the uptake and kinetics of liposomes into solid tumors and tumor vasculature. Experiments were performed in the amelanotic hamster melanoma A‐Mel‐3 growing in the dorsal skinfold chamber preparation of male Syrian golden hamsters. Fluorescently labeled liposomes with different surface charge were prepared. Accumulation of i.v. injected liposomes was assessed by quantitative intravital fluorescence microscopy of tumor and surrounding host tissue. The histological distribution of liposomes was analyzed by double‐fluorescence microscopy 20 min after application of fluorescently labeled lectin as a vascular marker. After i.v. application of anionic and neutral liposomes, we observed an almost homogeneous distribution of liposome‐induced fluorescence throughout the chamber preparation without specific targeting to tumor tissue. In contrast, cationic liposomes exhibited a significantly enhanced accumulation in tumor tissue and tumor vasculature up to 3‐fold compared to surrounding tissue (p<0.05). The histological distribution of neutral and anionic liposomes revealed extravasation 20 min after i.v. injection, while cationic liposomes displayed a highly selective accumulation on the vascular endothelium. In conclusion, cationic liposomes exhibited a preferential uptake in angiogenic tumor vessels and therefore may provide an efficient tool for the selective delivery of diagnostic or therapeutic agents to angiogenic blood vessels of solid tumors. On the other hand, anionic and neutral liposomes may be used as carriers of drugs to the extravascular compartment of tumors due to their extravasation.
International Journal of Cancer | 2004
Sebastian Strieth; Martin E. Eichhorn; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Marc Dellian
Cationic liposomes have been shown to be internalized selectively by angiogenic tumor endothelial cells after intravenous injection. Therefore, encapsulation of cytotoxic substances in cationic liposomes is a new approach to target tumor vasculature. It was the aim of our study to quantify the effects of paclitaxel encapsulated in cationic liposomes (MBT‐0206) on tumor microvasculature and growth in vivo. Experiments were performed in the dorsal skinfold chamber preparation of Syrian Golden hamsters bearing syngeneic A‐Mel‐3 melanomas. Tumors were treated with intravenous infusion of MBT‐0206 (20 mM) resulting in an effective paclitaxel dose of 5 mg/kg body weight (b.w.). Control animals received conventional paclitaxel in Cremophor EL (Taxol®; 5 mg/kg b.w.), unloaded cationic liposomes (20 mM) or the solvent 5% glucose, respectively. Using intravital microscopy, tumor growth and effects on intratumoral microvasculature were analyzed. Tumor growth was significantly retarded after treatment with MBT‐0206 compared to the treatment with paclitaxel. Analysis of intratumoral microcirculation revealed a reduced functional vessel density in tumors after application of liposomal paclitaxel. At the end of the observation time, vessel diameters were significantly smaller in animals treated with paclitaxel encapsulated in cationic liposomes while red blood cell velocity was less affected. This resulted in a significantly reduced blood flow in vessel segments and a reduced microcirculatory perfusion index in these animals. Histochemical TUNEL stain was vessel‐associated after treatment with liposomal paclitaxel in contrast to few apoptotic tumor cells in the control groups. Our data demonstrate that encapsulation of paclitaxel in cationic liposomes significantly increased the antitumoral efficacy of the drug. Remarkable microcirculatory changes indicate that encapsulation of paclitaxel in cationic liposomes resulted in a mechanistic switch from tumor cell toxicity to an antivascular therapy.
Clinical Cancer Research | 2003
Marcus Schmitt-Sody; Sebastian Strieth; Senat Krasnici; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Kurt Naujoks; Marc Dellian
Archive | 2001
Brita Schulze; Birgitta Sauer; Marc Dellian; Uwe Michaelis; Michael Teifel; Kurt Naujoks; Claudia Biro
Molecular Vision | 2013
Nikolai Gross; Mahdy Ranjbar; Charlotte Evers; Jing Hua; Gottfried Martin; Brita Schulze; Uwe Michaelis; Lutz L. Hansen; Hansjürgen T. Agostini
Archive | 2003
Carsten Mundus; Christian Welz; Oliver Schramel; Heinrich Haas; Thomas Fichert; Brita Schulze; Toralf Peymann; Uwe Michaelis; Michael Teifel; Friedrich Gruber; Gerhard Winter
Archive | 2007
Brita Schulze; Uwe Michaella; Hansjürgen Agostini; Jing Hua; Eric Guenzi; Gottfried Martin; Lutz Hansen
Molecular Vision | 2012
Jing Hua; Nikolai Gross; Brita Schulze; Uwe Michaelis; Hermann Bohnenkamp; Eric Guenzi; Lutz L. Hansen; Gottfried Martin; Hansjürgen T. Agostini
Archive | 2003
Heinrich Haas; Brita Schulze; Uwe Michaelis; Michael Teifel; Birgitta Sauer; Thomas Fichert
Archive | 2003
Heinrich Haas; Thomas Fichert; Brita Schulze; Toralf Peymann; Uwe Michaelis; Michael Teifel